よむ、つかう、まなぶ。
資料4-2 セトロレリクス酢酸塩 (12 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/shingi2/0000198856_00022.html |
| 出典情報 | 医薬・生活衛生局が実施する検討会 医療上の必要性の高い未承認薬・適応外薬検討会議（第50回 1／26）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
Gynecol Reprod Biol 2005; 120: 185-9.
11） Ernesto Escudero, et al. Comparison of two different starting multiple dose gonadotropinreleasing hormone antagonist protocols in a selected group of in vitro fertilization-embryo
transfer patients. Fertil Steril 2004; 81: 562-6.
12） Raffaella Depalo, et al. Endogenous luteinizing hormone concentration and IVF outcome during
ovarian stimulation in fixed versus flexible GnRH antagonist protocols: An RCT. Int J Reprod
BioMed 2018;16:175-82.
13） Molina B. Dayal, et al. The use of lead follicle diameter to initiate gonadotropin-releasing
hormone antagonist does not affect in vitro fertilization clinical pregnancy, implantation, or live
birth rates: a prospective, randomized study. Fertil Steril 2009; 92: 2047-9.
14） Gonadotrophin‐releasing hormone antagonists for assisted reproductive technology. Cochrane
Database Syst Rev 2016; 4: CD006919.
15） Textbook of Assisted Reproduction. Springer; 2020. p90.
16） 生殖医療ガイドライン. 一般社団法人日本生殖医学会; 2021. p29-31.
17） Tomoko Inoue, et al. Cabergoline administration prevents development of moderate to severe
ovarian hyperstimulation syndrome and it contributes to reduction in ovarian volume. Reprod
Med Biol. 2015; 14: 79-84.
18） Nanako Iwami, et al. New trial of progestin‑primed ovarian stimulation using dydrogesterone
versus a typical GnRH antagonist regimen in assisted reproductive technology. Arch Gynecol
Obstet. 2018; 298: 663-71.
19） Takahashi K, et al. GnRH Antagonist Improved Blastocyst Quality and Pregnancy Outcome
After Multiple Failures of IVF/ICSI–ET with a GnRH Agonist Protocol. J Assist Reprod Genet
2004; 21: 317-22.
20） Atsushi Yanaihara, et al. The decrease of serum luteinizing hormone level by a gonadotropinreleasing hormone antagonist following the mild IVF stimulation protocol for IVF and its
clinical outcome. J Assist Reprod Genet (2008) 25:115–118
21）A. Oride, et al. Comparison of human menopausal gonadotropin stimulation with and without
clomiphene for invitro fertilisation in poor-responders. Journal of Obstetrics and Gynaecology,
February 2015; 35: 163–167
12
11） Ernesto Escudero, et al. Comparison of two different starting multiple dose gonadotropinreleasing hormone antagonist protocols in a selected group of in vitro fertilization-embryo
transfer patients. Fertil Steril 2004; 81: 562-6.
12） Raffaella Depalo, et al. Endogenous luteinizing hormone concentration and IVF outcome during
ovarian stimulation in fixed versus flexible GnRH antagonist protocols: An RCT. Int J Reprod
BioMed 2018;16:175-82.
13） Molina B. Dayal, et al. The use of lead follicle diameter to initiate gonadotropin-releasing
hormone antagonist does not affect in vitro fertilization clinical pregnancy, implantation, or live
birth rates: a prospective, randomized study. Fertil Steril 2009; 92: 2047-9.
14） Gonadotrophin‐releasing hormone antagonists for assisted reproductive technology. Cochrane
Database Syst Rev 2016; 4: CD006919.
15） Textbook of Assisted Reproduction. Springer; 2020. p90.
16） 生殖医療ガイドライン. 一般社団法人日本生殖医学会; 2021. p29-31.
17） Tomoko Inoue, et al. Cabergoline administration prevents development of moderate to severe
ovarian hyperstimulation syndrome and it contributes to reduction in ovarian volume. Reprod
Med Biol. 2015; 14: 79-84.
18） Nanako Iwami, et al. New trial of progestin‑primed ovarian stimulation using dydrogesterone
versus a typical GnRH antagonist regimen in assisted reproductive technology. Arch Gynecol
Obstet. 2018; 298: 663-71.
19） Takahashi K, et al. GnRH Antagonist Improved Blastocyst Quality and Pregnancy Outcome
After Multiple Failures of IVF/ICSI–ET with a GnRH Agonist Protocol. J Assist Reprod Genet
2004; 21: 317-22.
20） Atsushi Yanaihara, et al. The decrease of serum luteinizing hormone level by a gonadotropinreleasing hormone antagonist following the mild IVF stimulation protocol for IVF and its
clinical outcome. J Assist Reprod Genet (2008) 25:115–118
21）A. Oride, et al. Comparison of human menopausal gonadotropin stimulation with and without
clomiphene for invitro fertilisation in poor-responders. Journal of Obstetrics and Gynaecology,
February 2015; 35: 163–167
12